Posting of Annual Report & Notice of AGM

RNS Number : 0733G

Eden Research plc

31 May 2013

 



Eden Research Plc

("Eden" or "Company")

Posting of Annual Report & Notice of AGM

Eden Research plc (AIM: EDEN), the AIM listed agrochemical and encapsulation development company, announces that the Annual Report and Accounts for the year ended 31 December 2012, the Notice of the Annual General Meeting ("AGM") and a Form of Proxy are being posted to shareholders and will be available on the Company's website shortly: www.edenresearch.com 

The AGM will be held at The Farmers' Club, 3 Whitehall Court, London, SW1A 2EL at 12.00pm on 24 June 2013.

Enquiries:

Eden Research plc	www.edenresearch.com
Clive Newitt, Managing Director	Tel: [phone]
Alex Abrey, Chief Financial Officer
W H Ireland Limited	Tel: [phone]
John Wakefield Mike Coe
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus (Media Relations)	Mob: [phone]
Paul Cornelius (Investor Relations)	Mob: [phone]

Notes:

Eden has developed a terpene-based encapsulation technology which uses yeast cells to deliver a slow release of natural compounds for agricultural and non-agricultural uses.

Terpenes are natural compounds which function as defence mechanisms in many plant groups and are released in response to infection, attack by pests, stress or mechanical injury. Terpenes are already widely used in the food flavouring, cosmetic and pharmaceutical industries.

Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.

A key milestone for the business was reached in May 2013 when the three active substances used in the Company's lead product, 3AEY, were approved for use in plant protection products within the European Union.

This allows the actives to be used with Eden's encapsulation technology in any combination to create a range of agrochemical products for a variety of applications.

The next-generation encapsulation technology, licensed from University of Massachusetts Medical School ("UMMS") recently, provides significant additional benefits to the original system as it allows release to be controlled by environmental factors rather than relying solely upon the chemistry of the substances used. This means that there is more control over the timing of the release of the active compound being carried allowing for further reduction in chemicals applied whilst ensuring maximum effectiveness.

The UMMS license also significantly expands the potential use of the Eden technology in non-agricultural applications such as health and beauty, cosmetics and animal health.

For more information about Eden, please visit www.edenresearch.com 

 

END

 

 

MSCZMGFKVMMGFZM